A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.
Inclusion Criteria:
Exclusion Criteria:
Mesa, Arizona 85210, United States
Tucson, Arizona 85712, United States
Washington D.C., District of Columbia 20011, United States
Minneapolis, Minnesota 55404, United States
Cincinnati, Ohio 45219, United States
Tahlequah, Oklahoma 74464, United States
CABA, Buenos Aires C1039AAO, Argentina
Caba, Buenos Aires C1128AAF, Argentina
CABA, Buenos Aires C1199ABB, Argentina
Mar del Plata, Buenos Aires B7600FZO, Argentina
San Nicolás de los Arroyos, Buenos Aires B2900DPA, Argentina
Rosario, Santa Fe Province 2000, Argentina
Manaus, Amazonas 69040-000, Brazil
Campo Grande, Mato Grosso do Sul 79070-900, Brazil
Ijuí, Rio Grande do Sul 98700-000, Brazil
São José do Rio Preto, São Paulo 15090000, Brazil
Rio de Janeiro, 22780-192, Brazil
Bogota, Cundinamarca 110411, Colombia
Pereira, Risaralda Department 660003, Colombia
Bucaramanga, Santander Department 681004, Colombia
Santo Domingo, Nacional 10605, Dominican Republic
Cairo, Cairo Governorate 11796, Egypt
Cairo, Cairo Governorate 11835, Egypt
Fort-de-France, Martinique 97200, France
Guatemala City, 01009, Guatemala
Debrecen, Hajdú-Bihar 4031, Hungary
Ginowan, Okinawa 901-2214, Japan
Tomigusuku, Okinawa 901-0224, Japan
Tokyo, 162-8655, Japan
Mexico City, Mexico City 14080, Mexico
General Escobedo, Nuevo León 66055, Mexico
Cancún, Quintana Roo 77500, Mexico
La Perla, Qallaw 07011, Peru
Muntinlupa, National Capital Region 1780, Philippines
Saint Petersburg, Sankt-Peterburg 196143, Russia
Saint Petersburg, Sankt-Peterburg 197376, Russia
Saint-Petrsburg, Sankt-Peterburg 190013, Russia
Saint-Petrsburg, Sankt-Peterburg 192289, Russia
Kazan', Tatarstan, Respublika 420140, Russia
Yaroslavl, Yaroslavl Oblast 150001, Russia
Johannesburg, Gauteng 2041, South Africa
Moloto, Gauteng 1022, South Africa
Mpumalanga, Gauteng 1055, South Africa
Phutthamonthon, Changwat Nakhon Pathom 73170, Thailand
Halkali/K.cekmece, Istanbul 34303, Turkey (Türkiye)
Istanbul, 34785, Turkey (Türkiye)
Ivano-Frankivsk, Ivano-Frankivsk Oblast 76007, Ukraine
Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
Ivano-Frankivsk, Ivano-Frankivsk Oblast 76025, Ukraine
Kharkiv, Kharkiv Oblast 61002, Ukraine
Kharkiv, Kharkiv Oblast 61172, Ukraine
Kyiv, Kyivska Oblast 01033, Ukraine
Kyiv, Kyivska Oblast 02232, Ukraine
Kyiv, Kyivska Oblast 03049, Ukraine
Lviv, Lviv Oblast 79011, Ukraine
Odesa, Odesa Oblast 65014, Ukraine
Odesa, Odesa Oblast 65025, Ukraine
Poltava, Poltava Oblast 36011, Ukraine